Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study

Although uncontrolled hyperglycaemia during pregnancy can cause complications for both the mother and her offspring, pharmacological treatment options for gestational and type 2 diabetes in pregnancy are still limited. Empagliflozin (EMPA), dapagliflozin (DAPA) and canagliflozin (CANA) are three sod...

Full description

Bibliographic Details
Main Authors: Sabrina Kuoni, Regula Steiner, Lanja Saleh, Roger Lehmann, Nicole Ochsenbein-Kölble, Ana Paula Simões-Wüst
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Biomedicine & Pharmacotherapy
Subjects:
SGLT2 inhibitors
Empagliflozin
Dapagliflozin
Canagliflozin
Pregnancy
Diabetes
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332224000581

Similar Items

Similar Items